|
|
|
|
|
16.02.26 - 17:51
|
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LR
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for treatment-resistant schizophreniaMILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening the Company's financial position as it advances the ENIGMA-TRS Phase III program.
Under the agreement, the investor group will initially subscribe to up to 779,624 newly issued shares at a subscription price of EUR 19.24 per sha...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 07:03
|
Corporate News: Newron Pharmaceuticals S.p.A. (EQS)
|
|
|
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
